Excision BioTherapeutics to Present Positive Data from its HSV-1 Keratitis Program, EBT-104, at the ASGCT 2024 Annual Meeting
April 22, 2024 16:31 ET
|
Excision BioTherapeutics
Oral presentation to discuss CRISPR-associated gene editing inactivating herpes virusTwo poster presentations highlight the potential of EBT-104 for the treatment of HSV-1 Keratitis, demonstrating...
Excision BioTherapeutics Announces Oral Presentation Highlighting Positive Data from its HBV Program, EBT-107, at the Upcoming ASGCT 2024 Annual Meeting
April 22, 2024 16:30 ET
|
Excision BioTherapeutics
SAN FRANCISCO, April 22, 2024 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc. (“Excision”, the “Company”), a clinical-stage biotechnology company developing CRISPR-based therapies to cure serious...
Excision BioTherapeutics Announces Oral Presentation of Preclinical HSV-1 Keratitis Data at CRISPRMED24 Conference on April 24, 2024
April 22, 2024 08:00 ET
|
Excision BioTherapeutics
SAN FRANCISCO, April 22, 2024 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc. (“Excision”, the “Company”), a clinical-stage biotechnology company developing CRISPR-based therapies to cure serious...
Excision BioTherapeutics Announces Oral Presentation of HSV-1 Keratitis Data at CRISPRMED24 Conference on April 24 2024
April 16, 2024 08:00 ET
|
Excision BioTherapeutics
SAN FRANCISCO, April 16, 2024 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc. (“Excision”, the “Company”), a clinical-stage biotechnology company developing CRISPR-based therapies to cure serious...
Excision BioTherapeutics Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
April 10, 2024 08:00 ET
|
Excision BioTherapeutics
Excision to give three oral presentations and outline new data in three posters from preclinical programs for herpes keratitis (HSV-1 Keratitis) and hepatitis B virus (HBV) as well as a...
Excision BioTherapeutics Presents Positive Interim Clinical Data from Ongoing Phase 1/2 Trial of EBT-101 for the Treatment of HIV at ESGCT 30th Annual Congress
October 25, 2023 08:30 ET
|
Excision BioTherapeutics
Excision reported positive safety and biodistribution data to 48 weeks in the first-in-human Phase 1/2 clinical evaluation of EBT-101No serious adverse events or dose-limiting toxicities were seen in...
Excision BioTherapeutics Announces Presentation of Interim Clinical Data for EBT-101 in Latent HIV at Upcoming European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress
October 19, 2023 07:50 ET
|
Excision BioTherapeutics
SAN FRANCISCO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies to cure viral infectious diseases,...
Excision BioTherapeutics Announces Gene Therapy Publication of Pre-Clinical Data Supporting its First-in-Class CRISPR-Based Gene Therapy Candidate Designed to Functionally Cure HIV-1
August 17, 2023 07:30 ET
|
Excision BioTherapeutics
Results demonstrate safety, biodistribution, and on-target editing of simian immunodeficiency virus (SIV) in non-human primatesData are a key component of scientific rationale supporting the ongoing...
Excision BioTherapeutics Receives FDA Fast Track Designation for EBT-101, a First-in-Class CRISPR-Based Gene Therapy Candidate to Functionally Cure HIV-1
July 20, 2023 07:00 ET
|
Excision BioTherapeutics
EBT-101 is a potentially curative, one-time CRISPR-based treatment which makes two cuts in integrated retroviral DNA to remove large portions of the HIV genome and prevent HIV from escaping and...
Excision BioTherapeutics Appoints Former Pfizer Chairman and CEO Jeffrey B. Kindler to its Board of Directors
June 01, 2023 09:00 ET
|
Excision BioTherapeutics
SAN FRANCISCO, June 01, 2023 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies designed to cure viral infectious diseases,...